CCM2

Future Espace Riopelle at MNBAQ: Architectural Design Competition Finalists Revealed

Retrieved on: 
Thursday, May 19, 2022
Tirpitz Museum (Denmark), Verdun Auditorium, The Jimmy Stewart Museum, Circuit, Architecture, Creativity, Expo 67, Cirque du Soleil, MacFarlane, Government, Bjarke Ingels Group, Muses, Galeries Lafayette, Cirque, Orange Cube, Quality of life, Circuit Gilles Villeneuve, Transport, Museum, Research, Lemay, Grand Prix, Bangladesh Technical Education Board, Tirpitz Museum, M/S Maritime Museum of Denmark, Cobe, Partnership, Kistefos Museum and Sculpture Park, BIG, Euronews, Suite (music), CCM2, Kistefos Wood Pulp Mill, Communication, NOMA, State-owned enterprise, Buckminster Fuller, Expo, Old Port, Private sector, Caisse, MNBAQ, Compliance, The, Furniture, Film, Interior design, Construction, Industrial design, Culture

BGLA was

Key Points: 
  • BGLA was
    one of the four finalists selected as part of the architectural design competition conducted for MNBAQ's Pierre Lassonde pavilion inaugurated in 2016.
  • Its creative approach revolves around a distinctive signature where design and performance are at the center of its projects.
  • In collaboration with the Jean Paul Riopelle Foundation's team, MNBAQ will complete the creative stages by conducting an integrated design process.
  • The inauguration of Espace Riopelle, scheduled for 2025, will be the culmination of the celebrations surrounding Jean Paul Riopelle's centenary.

Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation

Retrieved on: 
Tuesday, July 10, 2018
Benign neoplasms, Cavernous hemangioma, Medicine, Cavernous sinus, Angioma, Clinical medicine, Central nervous system cavernous hemangioma, CCM2

Later this year, Recursion plans to initiate the company's first clinical trial to evaluate the safety and pharmacokinetics of REC-994 as an oral treatment for CCM.

Key Points: 
  • Later this year, Recursion plans to initiate the company's first clinical trial to evaluate the safety and pharmacokinetics of REC-994 as an oral treatment for CCM.
  • Cerebral cavernous malformations (CCMs) are collections of small blood vessels in the brain that are enlarged and irregular in structure which lead to altered blood flow.
  • "A non-surgical treatment for cerebral cavernous malformation could have a significant impact on patients' lives," said Angioma Alliance President Dr. Connie Lee.
  • "We are excited about this important milestone and our continued work with Recursion to advance a novel oral treatment into clinical trials."